CORRECTED: Rival Drug Didn't Infringe Genzyme's Arthritis Patent: Jury
A federal jury in Massachusetts found Friday that drugmakers Seikagaku Corp. and Zimmer Inc. hadn't infringed Genzyme Corp.'s patent for osteoarthritis knee pain treatment Synvisc-One by marketing a rival pain treatment....To view the full article, register now.
Already a subscriber? Click here to view full article